Activating point mutations in RET can lead to the hereditary cancer syndrome called multiple endocrine neoplasia type 2 (MEN 2) [144], and chromosomal rearrangements involving RET and other proteins can lead to the constitutive activation of RET, primarily being associated with malignancies such as papillary thyroid carcinoma [145]. This evidence concerns the gene RET and multiple endocrine neoplasia type 2.